{"id":"oxaliplatin-irinotecan-folinic-acid-fluorouracil","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-20%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, causing DNA damage and apoptosis in cancer cells. Irinotecan is a topoisomerase I inhibitor that prevents DNA replication and repair, while folinic acid (leucovorin) enhances the effectiveness of fluorouracil by stabilizing the ternary complex of thymidylate synthase, fluorouracil, and folate. Fluorouracil is a thymidylate synthase inhibitor that blocks DNA synthesis and repair, leading to cell death.","oneSentence":"Oxaliplatin, irinotecan, folinic acid, and fluorouracil work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:10.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of stage III colon cancer"},{"name":"First-line treatment of metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT07490301","phase":"PHASE2, PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":900},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT05179889","phase":"PHASE2, PHASE3","title":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","status":"RECRUITING","sponsor":"Chungnam National University Hospital","startDate":"2021-07-06","conditions":"Colon Cancer Stage III","enrollment":308},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":"Unresectable Pancreatic Cancer","enrollment":90},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Pancreatic Cancer Resectable","enrollment":30},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT05677490","phase":"PHASE3","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-01-31","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":382},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT06951503","phase":"PHASE3","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-27","conditions":"Colorectal Adenocarcinoma","enrollment":560},{"nctId":"NCT05846867","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":"Colorectal Cancer","enrollment":170},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":"Colorectal Adenocarcinoma","enrollment":455},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Liver Metastases From Colorectal Cancer (mCRC)","enrollment":16},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT07415031","phase":"PHASE2","title":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","status":"NOT_YET_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2026-05-16","conditions":"Solid Tumors","enrollment":170},{"nctId":"NCT05466799","phase":"PHASE2","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoSil Medical Limited","startDate":"2023-04-26","conditions":"Locally Advanced Pancreatic Cancer","enrollment":88},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03983057","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":392},{"nctId":"NCT04340141","phase":"PHASE3","title":"Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2020-10-13","conditions":"Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer","enrollment":358},{"nctId":"NCT07214298","phase":"PHASE1, PHASE2","title":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":35},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":35},{"nctId":"NCT05546853","phase":"PHASE1","title":"Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2023-03-28","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":43},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT00556413","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":42},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT06381154","phase":"PHASE2","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-06","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":25},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":"Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma","enrollment":167},{"nctId":"NCT06574620","phase":"NA","title":"Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-11-28","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT07042685","phase":"PHASE2","title":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT05688215","phase":"PHASE1, PHASE2","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2023-03-07","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":56},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT07340151","phase":"NA","title":"Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07056777","phase":"PHASE1, PHASE2","title":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Zhejiang Doer Biologics Co., Ltd.","startDate":"2025-03-25","conditions":"Gastrointestinal Cancer","enrollment":186},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT07325214","phase":"NA","title":"Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"IMGT Co., Ltd.","startDate":"2026-04","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer","enrollment":136},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT03322995","phase":"PHASE2","title":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2018-06-21","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT06821997","phase":"PHASE2","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-02-01","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT06586515","phase":"PHASE1","title":"MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-12","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":630},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT07284277","phase":"PHASE1, PHASE2","title":"TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","status":"RECRUITING","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2025-10-14","conditions":"Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT07277842","phase":"PHASE3","title":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-29","conditions":"Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)","enrollment":382},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT05358704","phase":"PHASE2","title":"Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer","status":"SUSPENDED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-05-13","conditions":"Cancer of Rectum","enrollment":38},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06846346","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-20","conditions":"Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma","enrollment":88},{"nctId":"NCT03279237","phase":"PHASE1","title":"A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-24","conditions":"GastroEsophageal Cancer","enrollment":25},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT02967289","phase":"PHASE3","title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-27","conditions":"Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)","enrollment":792},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT04008030","phase":"PHASE3","title":"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-05","conditions":"Metastatic Colorectal Cancer","enrollment":839},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT04361708","phase":"PHASE1","title":"Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2020-05-08","conditions":"Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma","enrollment":54},{"nctId":"NCT06896188","phase":"PHASE1","title":"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2025-09-22","conditions":"Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT07096362","phase":"PHASE2","title":"Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-09","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT05610163","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-12-08","conditions":"Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":783},{"nctId":"NCT07150403","phase":"PHASE2","title":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-31","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":74},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT05585320","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immuneering Corporation","startDate":"2022-10-31","conditions":"Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)","enrollment":209},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT00492999","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-05","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":85,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"oxaliplatin, irinotecan, folinic acid, fluorouracil","genericName":"oxaliplatin, irinotecan, folinic acid, fluorouracil","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaliplatin, irinotecan, folinic acid, and fluorouracil work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer, First-line treatment of metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}